TY - JOUR
T1 - Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network
AU - Denlinger, Loren C.
AU - Sorkness, Christine A.
AU - Chinchilli, Vernon M.
AU - Lemanske, Robert F.
N1 - Funding Information:
(Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation)
Funding Information:
The Asthma Clinical Research Network (I) is supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) grants 5U10HL051845, 5U10HL051831, 5U10HL051834, 5U10HL051843, 5U10HL056443, 5U10HL051810, and 5U10HL051823. The Childhood Asthma Research and Education Network is also funded by NIH/NHLBI through grants 5U10HL064313, 5U10HL064288, 5U10HL064305, 5U10HL064295, 5U10HL064287, and 5U10HL064307.
Funding Information:
The Asthma Clinical Research Network (ACRN) and the Childhood Asthma Research and Education (CARE) Network were initiated in 1993 and 1999, respectively, from requests for proposals that were developed and funded by the National Heart, Lung, and Blood Institute. The ACRN and the CARE Network were developed to specifically address therapeutic issues in asthma in both adults and children based on concerns related to the increase in the incidence and prevalence of worldwide asthma and in response to clinical researchers who desired a mechanism by which dispassionate therapeutic trials in asthma could be conducted to answer important and relevant therapeutic questions that were unlikely to be addressed by industry.
PY - 2007/1
Y1 - 2007/1
N2 - Because of an increasing prevalence, morbidity, and mortality associated with asthma, the National Heart, Lung, and Blood Institute created the Asthma Clinical Research Network and the Childhood Asthma Research and Education Network to improve public health. The objectives of these clinical research networks are to conduct multiple, well-designed clinical trials for rapid evaluation of new and existing therapeutic approaches to asthma and to disseminate laboratory and clinical findings to the health care community. These trials comprise a large proportion of the data driving the treatment guidelines established and reviewed by the National Asthma Education and Prevention Program. This article will review the basic design and major findings of selected Asthma Clinical Research Network and Childhood Asthma Research and Education Network trials involving both adults and children with asthma. Collectively, these studies have helped refine the therapeutic role of existing controller medications, establish standard models for side-effect evaluation and risk-benefit models, validate symptom-based assessments for asthma control, and identify baseline characteristics that might predict individual patient responses. Remaining challenges include shaping the role of novel therapeutics in future guidelines, incorporating pharmacogenomic data in treatment decisions, and establishing better implementation strategies for translation to community settings, all with the goal of reducing the asthma burden on society.
AB - Because of an increasing prevalence, morbidity, and mortality associated with asthma, the National Heart, Lung, and Blood Institute created the Asthma Clinical Research Network and the Childhood Asthma Research and Education Network to improve public health. The objectives of these clinical research networks are to conduct multiple, well-designed clinical trials for rapid evaluation of new and existing therapeutic approaches to asthma and to disseminate laboratory and clinical findings to the health care community. These trials comprise a large proportion of the data driving the treatment guidelines established and reviewed by the National Asthma Education and Prevention Program. This article will review the basic design and major findings of selected Asthma Clinical Research Network and Childhood Asthma Research and Education Network trials involving both adults and children with asthma. Collectively, these studies have helped refine the therapeutic role of existing controller medications, establish standard models for side-effect evaluation and risk-benefit models, validate symptom-based assessments for asthma control, and identify baseline characteristics that might predict individual patient responses. Remaining challenges include shaping the role of novel therapeutics in future guidelines, incorporating pharmacogenomic data in treatment decisions, and establishing better implementation strategies for translation to community settings, all with the goal of reducing the asthma burden on society.
UR - http://www.scopus.com/inward/record.url?scp=33846018406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846018406&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2006.10.015
DO - 10.1016/j.jaci.2006.10.015
M3 - Review article
C2 - 17141853
AN - SCOPUS:33846018406
SN - 0091-6749
VL - 119
SP - 3
EP - 11
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 1
ER -